ClinicalTrials.gg

Program

plinabulin

Also written as “Plinabulin”, “Docetaxel + Plinabulin (DP)” and “NPI-2358 + docetaxel”.

Its studies are mostly in Neutropenia · Carcinoma, Non-Small-Cell Lung · Neoplasms · Lymphoma, led by 2 companies.

Furthest: phase 3, since Jul 16, 20158 company-led studies, 2 open or runningNext primary completion: Jun 1, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeyondSpring Pharmaceuticals62 open or runningphase 3since Jul 16, 2015Jul 16, 2015Jun 1, 2029phase 3 · NCT07361484
Nereus Pharmaceuticals20 open or runningphase 2since Feb 26, 2008May 4, 2006none ahead

Also a collaborator on its studies: covance and icon-plc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 4, 2006First study: phase 1 study in NeoplasmsNew to Nereus PharmaceuticalsNereus Pharmaceuticals · NCT00322608 · 35 enrolled · United States
  2. Feb 26, 2008Phase 2 study in NeoplasmsNereus Pharmaceuticals · NCT00630110 · 172 enrolled · United States, Argentina, Australia and more
  3. Jul 16, 2015BeyondSpring Pharmaceuticals's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to BeyondSpring PharmaceuticalsBeyondSpring Pharmaceuticals · NCT02504489 · 559 enrolled · United States, Australia, China
  4. Mar 6, 2017Phase 3 study in Chemotherapy-induced NeutropeniaBeyondSpring Pharmaceuticals · NCT03102606 · 105 enrolled · United States, China, Russian Federation and more
  5. Sep 22, 2017Phase 3 study in Chemotherapy-induced NeutropeniaBeyondSpring Pharmaceuticals · NCT03294577 · 221 enrolled · China, Ukraine
  6. Jan 10, 2020Phase 2 study in Chemotherapy-induced NeutropeniaBeyondSpring Pharmaceuticals · NCT04227990 · 115 enrolled · China, Ukraine
  7. Mar 31, 2020Phase 2 study in Chemotherapy-induced NeutropeniaBeyondSpring Pharmaceuticals · NCT04345900 · 55 enrolled · United States, China, Russian Federation and more
  8. Jan 19, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungBeyondSpring Pharmaceuticals · NCT07361484 · 442 planned

Ahead

  1. Jun 1, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBeyondSpring Pharmaceuticals · NCT07361484

TargetBeta

“Tubulin inhibitor”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
DocetaxelruleSanofiphase 4199
cabazitaxelruleSanofiphase 421
VinblastineruleTakedaphase 44
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07361484Carcinoma, Non-Small-Cell Lung3Not yet recruitingBeyondSpring PharmaceuticalsJun 1, 2029442
NCT04345900Chemotherapy-induced Neutropenia · United States, China, Russian Federation and more2CompletedBeyondSpring PharmaceuticalsMar 20, 201855
NCT04227990Chemotherapy-induced Neutropenia · China, Ukraine2CompletedBeyondSpring PharmaceuticalsOct 15, 2018115
NCT03294577Chemotherapy-induced Neutropenia · China, Ukraine3Active, not recruitingBeyondSpring PharmaceuticalsSep 25, 2020221
NCT03102606Chemotherapy-induced Neutropenia · United States, China, Russian Federation and more3CompletedBeyondSpring PharmaceuticalsDec 12, 2018105
NCT02504489Carcinoma, Non-Small-Cell Lung · United States, Australia, China3CompletedBeyondSpring PharmaceuticalsJul 21, 2021559
NCT00630110Neoplasms · United States, Argentina, Australia and more2CompletedNereus PharmaceuticalsJun 2011172
NCT00322608Neoplasms · United States1CompletedNereus PharmaceuticalsSep 200935

How it is read

Names in the registry

  • “Plinabulin”, 5 entries
  • “Docetaxel + Plinabulin (DP)”, 1 entry
  • “NPI-2358 + docetaxel”, 1 entry
  • “NPI-2358”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.